

17.06.2022

- 08:25 - 08:30 Welcome to the ESMO Gynaecological Cancers Congress 2022 Auditorium 1A**
Moderation: S. Banerjee¹, D. Lorusso², ¹The Royal Marsden Hospital - Chelsea, London, GB, ²Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT
- 08:30 - 10:00 Management of endometrial cancer in the molecular era Auditorium 1A**
Moderation: C. Creutzberg¹, M.R. Mirza², ¹LUMC - Universitair Medisch Centrum, Leiden, NL, ²Rigshospitalet, Copenhagen, DK
- 08:30 - 08:55 **Recent developments in surgery for early-stage disease**
C. Marth, Innsbruck Medical University, Innsbruck, AT
- 08:55 - 09:20 **Recent developments in adjuvant treatment**
C. Creutzberg, LUMC - Universitair Medisch Centrum, Leiden, NL
- 09:20 - 09:45 **New treatment options for advanced and metastatic disease**
A. Leary, Institut Gustave Roussy, Villejuif, FR
- 09:45 - 10:00 **Live Q&A**
- 10:30 - 12:00 Biomarkers in clinical practice and future perspective for gynaecological cancers Auditorium 1A**
Moderation: V. Makker¹, A. Cervantes², ¹Memorial Sloan-Kettering Cancer Center, New York City, US, ²Valencia, ES
- 10:30 - 10:50 **Should we really use PD-L1 as a selection driver in cervical cancer?**
B. Monk, Arizona Oncology (US Oncology Network), Phoenix, US
- 10:50 - 11:10 **MMR status, TMB or both: How to identify endometrial cancer patients who benefit the most from immunotherapy**
V. Makker, Memorial Sloan-Kettering Cancer Center, New York City, US
- 11:10 - 11:30 **Digging into molecular characterization of high-grade ovarian cancer: BRCA, HRD and beyond**
N. Concin, Landeskrankenhaus - Universitaetskliniken Innsbruck, Innsbruck, AT
- 11:30 - 11:50 **The role of MAPK pathway to select therapy in low-grade ovarian cancer**
S. Banerjee, The Royal Marsden Hospital - Chelsea, London, GB
- 11:50 - 12:00 **Live Q&A**

12:05 - 12:50	YO Mentorship: How to find the right mentor Moderation: A. Cervantes, Valencia, ES	Foyer
12:05 - 12:50	YO Mentorship: How to start an international collaboration Moderation: M.R. Mirza, Rigshospitalet, Copenhagen, DK	Foyer
12:05 - 12:50	YO Mentorship: How to find the right balance between your career and personal life Moderation: D. Lorusso, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT	Foyer
12:15 - 13:00	Poster Display session	Exhibition area

- 12:15 - 12:20 **1P - Comprehensive assessment of gene mutations revealed overlapping responses for PARPi and chemotherapy in ovarian cancer cells**
A. Tozzi¹, R. Coelho², M. Disler², F. Lombardo², A. Fedier², M. Nunez Lopez², F. Freuler², F. Jacob², V. Heinzelmann-Schwarz², ¹Universitatsspital Basel, Basel, CH, ²University Hospital Basel, Basel, CH
- 12:20 - 12:25 **2P - Spectrum of BRCA1, BRCA1, ATM and PALB2 alleles in ovarian cancer patients from North Caucasus**
E. Imyanitov¹, E. Bakayeva², A. Romanko², I. Stepanov², L. Sultanova³, Z. Khamgokov⁴, M. Bolieva⁵, A. Epkhiev⁵, M. Chakhkieva⁶, I. Khabriev⁶, M. Murachuev⁷, A. Sokolenko², ¹N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU, ²N.N. Petrov Institute of Oncology, Saint-Petersburg, RU, ³Chechen Republican Cancer Center, Groznyi, RU, ⁴Kabardino-Balkarian Republican Cancer Center, Nalchik, RU, ⁵North Ossetian Republican Cancer Center, Vladikavkaz, RU, ⁶Ingush Republican Cancer Center, Nazran, RU, ⁷Dagestan Republican Cancer Center, Makhchkala, RU
- 12:25 - 12:30 **3P - Identification of novel biomarkers of response to ATR inhibitors in ARID1A mutant ovarian clear cell carcinoma.**
J. Stewart¹, J. Baxter², D. Zatreanu², R. Brough², F. Song², A. Konde², D. Krastev², J. Alexander², R. Natrajan², S. Pettitt², S. Banerjee³, C. Lord², ¹ICR - Institute of Cancer Research, London, GB, ²ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB, ³The Royal Marsden Hospital - Chelsea, London, GB
- 12:30 - 12:35 **4P - Targeting PI3K/AKT/mTOR pathway in platinum-resistant ovarian high-grade serous carcinoma: Translational analysis from the randomized phase II OCTOPUS Trial.**
G. Giannone¹, D. Ennis², H.B. Mirza², Z. Cheng¹, J. Mcdermott¹, L.-A. Lewsley³, A. Clamp⁴, R. Herbertson⁵, R. Glasspool⁶, J. Krell⁷, S. Hinsley³, U. Banerji⁸, R. Riisnaes⁹, S. Banerjee¹⁰, I. Mcneish¹, ¹Imperial College London - Hammersmith Campus, London, GB, ²Imperial College London - Hammersmith Campus, London, GB, ³University of Glasgow, Glasgow, GB, ⁴The Christie NHS Foundation Trust, Manchester, GB, ⁵Sussex Cancer Centre - Royal Sussex County Hospital, Brighton, GB, ⁶BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, ⁷Hammersmith Hospital, London, GB, ⁸The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, ⁹ICR - Institute of Cancer Research, London, GB, ¹⁰The Royal Marsden Hospital - Chelsea, London, GB

- 12:35 - 12:40 **5P - HOX Gene Dysregulation in Endometrioid Ovarian Cancer**
P. Idaikkadar, A. Michael, University of Surrey - Faculty of Health and Medical Sciences, Guildford, GB
- 12:40 - 12:45 **6P - Urine Spectroscopy coupled with Artificial Intelligence: proof of concept for a new diagnostic tool to detect gynecological cancers**
F. Vigo¹, A. Tozzi², V. Kavvadias³, M. Disler³, T. Kavvadias³, ¹University Hospital Basel - Department of Biomedicine, Basel, CH, ²Universitatsspital Basel, Basel, CH, ³University Hospital Basel, Basel, CH
- 12:45 - 12:50 **7P - Improving Cervical Cancer Screening in Rural India Over a 5 Year Period by Training Paramedical Staff To Use Visual Inspection with Acetic Acid and Thermal Ablation: A Comparison of Cervical Cancer Rates Between Villages With and Without Training**
S. Menakuru¹, S. Kalla², ¹Indiana University Health Ball Memorial Hospital, Muncie, US, ²Maharaja Institute of Medical Sciences, Nellimarla, IN
- 12:50 - 12:55 **8P - 20 years of cervical cancer screening program and the impact on hospitalization rates in the public health system in a state of Brazil**
A.M. Silva, M. Nunes, UFS - Universidade Federal de Sergipe - Campus Aracaju, Aracaju, BR
- 12:55 - 13:00 **9P - A prospective study of Gefitinib in Patients With Recurrent or Metastatic Carcinoma Cervix**
A. Krishna¹, A. Ms², D. Fernandes³, H. Ag³, S. Rao³, S. Shankar³, S. Banerjee², J. Sunny², C. Srinivas², D. Lobo², ¹Mysore Medical College and Research Institute, Mysore, IN, ²Kasturba Medical College, Mangalore, IN, ³Father Muller Medical College, Mangalore, IN
- 13:00 - 13:05 **10P - Ten-year survival outcome and patterns of failure analysis of patients with localized adenocarcinoma cervix - Our experience from a tertiary cancer care center**
D. Simson, S. Mitra, H. Khurana, S. Barik, K. Dobriyal, A. Krishnan, P. Umesh, S. Pathi, A. Dewan, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN
- 13:05 - 13:10 **11P - Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer**
T. Golia D'Auge¹, V. Di Donato², A. Fracassi¹, I. Palaia¹, G. Perniola¹, L. Muzii¹, G. Scambia³, P. Benedetti Panici⁴, F. Raspagliesi⁵, G. Bogani⁶, ¹Sapienza - Università di Roma, Rome, IT, ²Universita La Sapienza, Rome, IT, ³Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ⁴Sapienza Università di Roma, Rome, IT, ⁵Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁶Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milano, MI, IT
- 13:10 - 13:15 **12P - Any size of lymph node metastasis should be considered N1 in patients with cervical cancer**
D. Cibula¹, K. Benešová², J. Klát³, H. Falconer⁴, S. Kim⁵, L. Van Lonkhuijzen⁶, A. Lopez⁷, D. Isla⁸, F. Landoni⁹, J. Kostun¹⁰, R. Dos Reis¹¹, D. Odetto¹², I. Zapardiel¹³, M.

Borcinová¹, J. Jarkovský², V. Javurková³, S. Salehi⁴, N. Abu-Rustum⁵, L. Dostálek¹,
¹General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, Prague, CZ, ²Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, CZ, ³Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, Czech Republic, Ostrava, CZ, ⁴Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institute, Stockholm, SE, ⁵Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA, New York, US, ⁶Department of Gynecological Oncology, Amsterdam University Medical Center—Center for Gynecological Oncology Amsterdam, Amsterdam, the Netherlands, Amsterdam, NL, ⁷Department of Gynecological Surgery, National Institute of Neoplastic Diseases, Lima, Peru, Lima, PE, ⁸Gynecology Oncology Center, National Institute of Cancerology Mexico, Mexico, Ciudad de Mexico, MX, ⁹University of Milano-Bicocca, Department of Obstetrics and Gynecology, Gynaecologic Oncology Surgical Unit, ASST-Monza, San Gerardo Hospital, Monza, Italy, Monza, IT, ¹⁰Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic, Plzen, CZ, ¹¹Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, Houston, US, ¹²Department of Gynecologic Oncology, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano, Buenos Aires, Argentina., Buenos Aires, AR, ¹³Gynecologic Oncology Unit, La Paz University Hospital - IdiPAZ, Madrid, Spain, Madrid, ES

- 13:15 - 13:20 **13P - Dosimetric comparisons of brachytherapy applicators used in carcinoma cervix and their utility in toxicity prediction**
N. Gokulanathan, J. Pandjatcharam, N. Patil, P. Udayakumar, L.K. Pothuboina, JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IN
- 13:20 - 13:25 **14P - A Prospective study of comparison of two HDR Brachytherapy regimens in treatment of cervical cancer**
A. Krishna¹, A. Ms², D. Fernandes³, H. Ag³, S. Rao³, S. Shankar³, S. Banerjee², J. Sunny², C. Srinivas², D. Lobo², ¹Mysore Medical College and Research Institute, Mysore, IN, ²Kasturba Medical College, Mangalore, IN, ³Father Muller Medical College, Mangalore, IN
- 13:25 - 13:30 **15P - N6-methyladenosine modification of YY1 mRNA promotes cervical cancer tumorigenesis**
P. Arumugam¹, V.P. Jayaseelan², ¹Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, IN, ²Saveetha Dental College & Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, IN
- 13:30 - 13:35 **16P - The role of IL-8 gene polymorphism (845 T/C) in the development of cervical intraepithelial neoplasia**
T. Abakumova, D. Dolgova, I. Myagdieva, S. Gening, I. Antoneeva, T. Gening, Ulyanovsk State University, Ulyanovsk, RU
- 13:35 - 13:40 **17P - Correlation between human papillomavirus clearance and complete response among Mexican patients with locally advanced cervical cancer treated with chemoradiotherapy**
M. Noriega Iriondo¹, J. Gonzalez Guerrero², J. Gonzalez Vela², D. Ruiz-Sánchez², M.

Zamudio-Osuna³, L.E. Martínez-De Villarreal¹, D. Hernandez Barajas², O. Vidal-Gutiérrez², C.E. Salazar-Mejía², ¹Hospital Universitario Dr José Eleuterio Gonzalez, Monterrey, MX, ²Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, MX, ³Bioss Celulas Madre S de RL de CV, San Pedro Garza García, MX

- 13:40 - 13:45 **18P - The role of BYL719 in PIK3CA-mutated cervical cancer**
G. Bogani¹, M. Bini², F. Raspagliesi³, ¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milano, MI, IT, ²Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ³Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
- 13:45 - 13:50 **19TiP - SGNTUC-019 Phase 2 basket study of tucatinib and trastuzumab in solid tumors with human epidermal growth factor receptor 2 alterations: uterine and cervical cancer cohorts**
D. O'Malley¹, F. Jin², J. Ramos³, Q. Tan⁴, B. Monk⁵, ¹OSUCCC - The Ohio State University Comprehensive Cancer Center - James, Columbus, US, ²Merck & Co., Inc. - Corporate Headquarters, Whitehouse Station, US, ³Seattle Genetics, Inc., Seattle, US, ⁴Seagen, Inc., Bothell, US, ⁵Arizona Oncology (US Oncology Network), Phoenix, US
- 13:50 - 13:55 **22P - A Comparison of New ESGO-ESTRO-ESP Endometrial Risk classification With Previous Classification in predicting outcome**
A. Prakasan, J. Krishna, A. Kumar, S. Mathews, S. Sambasivan, J. Joseph, F. James, RCC - Regional Cancer Centre, Thiruvananthapuram, Thiruvananthapuram, IN
- 13:55 - 14:00 **23P - Systematic Literature Review of Real-World Outcomes of Chemotherapies for Advanced or Recurrent Endometrial Cancer**
A. Kadambi¹, I. Pustulka², R. Hughes³, V.S. Prabhu⁴, Q. Zhao⁵, ¹Evidera - US Headquarters, Bethesda, US, ²Evidera - European Headquarters, London, GB, ³Evidera - San Francisco, San Francisco, US, ⁴Merck & Co. Inc., Kenilworth, US, ⁵Eisai Inc., Nutley, US
- 14:00 - 14:05 **24P - Somatic tumor testing informs on mismatch repair deficiency (MMR-D) phenotype in patients with endometrial cancer**
M. Salib¹, H. Habib², A. Ebrahim², K. Shohdy³, ¹Cairo University - Faculty Of Medicine, Cairo, EG, ²Cairo University, Cairo, EG, ³The University of Manchester, Manchester, GB
- 14:05 - 14:10 **25P - The impact of COVID-19 on delaying diagnostic-therapeutic pathways of endometrial cancer patients: the Italian real-world scenario**
V. Di Donato¹, G. Scambia², P. Benedetti Panici³, F. Raspagliesi⁴, G. Bogani⁵, ¹Universita La Sapienza, Rome, IT, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ³Sapienza Università di Roma, Rome, IT, ⁴Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁵Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milano, MI, IT
- 14:10 - 14:15 **26P - Uterine Sarcoma: A Retrospective Tunisian Study Of 103 Cases**
E. Ouertani¹, Y. Yahyaoui², Z. Ghodhbani², F. Letaief-Ksontini², A. Gabsi², K. Meddeb², M. Ayadi², A. Mokrani², N. Chraiet², H. Rais², Y. Zenzri², H. Ben Mansour², A. Mezlini²,

¹Hopital Abderrahmen Mami de Pneumo-Phtisiologie, Ariana, TN, ²Salah Azaiez Institute, Tunis, TN

- 14:15 - 14:20 **29P - Plasma tumor-derived small extracellular vesicles microRNAs plus CA-125 objectively detect residual disease risk after surgical debulking in advanced ovarian cancer**
J. Tang, Hunan Cancer Hospital, Changsha, CN
- 14:20 - 14:25 **30P - Molecular biomarkers by next generation sequencing predicting oncological outcomes in ovarian cancer patients**
S. Peleg Hasson, D. Hershkovitz, E. Shachar, M. Brezis, I. Wolf, T. Safra, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL
- 14:25 - 14:30 **31P - Survival outcomes in BRCA pathogenetic mutated, variant of unknown significance, and wild type ovarian cancer patients treated with PARP inhibitors**
L. Musacchio¹, C. Marchetti², S.M. Boccia², C. Cassani³, J. Ventriglia⁴, V. Salutari², F. Camarda², V. Ghizzoni², E. Giudice², M.V. Carbone², S. Pignata⁴, G. Scambia², D. Lorusso⁵, ¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ³Fondazione IRCCS Policlinico San Matteo, Pavia, IT, ⁴Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, IT, ⁵Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT
- 14:30 - 14:35 **32P - BRCA1/2 mutations in epithelial ovarian cancer: treatment response and survival analysis in an Spanish tertiary university hospital**
I. Miras Rodriguez, E. Calvo García, P. Estevez Garcia, Hospital Universitario Virgen del Rocio, Seville, ES
- 14:35 - 14:40 **33P - The Development of Infrastructure for Mainstream Ovarian Cancer Genetic Testing (DEMO)**
I. Funingana¹, E. Leung², M.-L. Alcaraz³, L. Bird⁴, J.E. Ang⁵, C. Parkinson⁶, M. Jimenez-Linan⁶, S. Freeman⁶, C. Spencer⁷, J. Winning², R. Ganesan², S. Williams⁸, K.R. Ong⁹, P. Abedin⁹, S. Sundar¹⁰, J. Balega², J. Brenton³, ¹University of Cambridge School of Clinical Medicine, Cambridge, GB, ²City Hospital - Sandwell and West Birmingham NHS Trust, Birmingham, GB, ³CRUK - Cancer Research UK Cambridge Institute - University of Cambridge, Cambridge, GB, ⁴The University of Birmingham - Medical School, Birmingham, GB, ⁵Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB, ⁶Addenbrooke's Hospital, Cambridge, GB, ⁷Sandwell General Hospital, West Bromwich, GB, ⁸University Hospitals Birmingham NHS Trust, Birmingham, GB, ⁹Birmingham Women's and Children's NHS Foundation Trust, Birmingham, GB, ¹⁰Institute of Cancer and Genomic Sciences - University of Birmingham, Birmingham, GB
- 14:40 - 14:45 **34P - Immunocytochemical determination of EpCAM protein expression in ascitic fluid cells in the diagnosis of ovarian cancer using the SER1 test system**
I. Kruglova¹, O. Utkin², S. Zinoviev³, ¹City Hospital No.35, Nizhny Novgorod, RU, ²Scientific Research Institute of Epidemiology and Microbiology, Nizhny Novgorod, RU, ³Regional Oncology Centre, Nizhny Novgorod, RU

- 14:45 - 14:50 **35P - Racial Disparities in Diagnosis, Histological Type, Treatment and Survival in Ovarian Cancer Patients in the US from 1992 to 2018: SEER-based Analysis.**
E. Zin Eldin, MFM-SRP, Menoufia, EG
- 14:50 - 14:55 **36P - Factors associated with platinum resistance in ovarian cancer patients receiving neoadjuvant chemotherapy**
Q. Gao¹, L. Xingyu², H. Ting², X. Jiao², Z. Yingjun², G. Ma², Y. Huo², L. Ming², Z. Peng², J. Chi², S. Zeng², Y. Yuyy², ¹Union Hospital, Tongji Medical College, Huazhong University of Science and Technology/Cancer Center Union Hospital, Wuhan, CN, ²Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology/ Cancer Center Union Hospital, Wuhan, CN
- 14:55 - 15:00 **37P - Obesity and ovarian cancer, a controversial risk factor**
F. Baidoun¹, J. Abdeldayem², A. Saad³, M. Sarmini¹, M. Gad¹, M. Alhaj Moustafa⁴, ¹Cleveland Clinic, Cleveland, US, ²Case Western Reserve, University Hospitals, Cleveland, US, ³Wayne State University, Detroit, US, ⁴Mayo Clinic-Florida, Jacksonville, US
- 15:00 - 15:05 **38P - Impact of 1-year COVID-19 pandemic in patients with ovarian carcinoma treated with chemotherapy based on a GLOBAL DATA NETWORK**
L. Manso Sanchez¹, A. Madariaga Urrutia¹, G. Hernández-Ibarburu², R. Sanchez Bayona¹, P. Tolosa Ortega¹, L. Lema Roso¹, M. Alva¹, A. Modrego¹, P. Serrano¹, L. Paz-Ares¹, ¹Hospital Universitario 12 de Octubre, Madrid, ES, ²UPM - Universidad Politecnica de Madrid - ETSIT, Madrid, ES
- 15:05 - 15:10 **39P - Longitudinal Increases in Albumin-Adjusted Serum Calcium Predict Ovarian Cancer**
G. Schwartz¹, D. Lutz², M. Bell³, M. Klug², ¹University of North Dakota School of Medicine, Grand Forks, ND, US, ²University of North Dakota - School of Medicine and Health Sciences, Grand Forks, US, ³Sanford Cancer Center, Sioux Falls, US
- 15:10 - 15:15 **40P - Exome sequencing analysis of primary and recurrent ovarian carcinomas**
E. Imyanitov¹, A. Sokolenko², T. Gorodnova², A. Ivantsov², I. Bizin², ¹N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU, ²N.N. Petrov Institute of Oncology, Saint-Petersburg, RU
- 15:15 - 15:20 **41P - Comprehensive genomic profiling in the management of ovarian cancer - national results from Croatia**
D. Cerina¹, V. Matkovic², K. Katic², I. Belac Lovasic³, R. Separovic⁴, I. Canjko⁵, Ž. Bajic⁶, E. Vrdoljak⁷, ¹Clinical Hospital Firule, Split, HR, ²KBC - University Hospital Centre Zagreb, Zagreb, HR, ³University Hospital KBC Rijeka, Rijeka, HR, ⁴University Hospital for Tumors, University Hospital Center Sestre Milosrdnice, Zagreb, HR, ⁵KBC Osijek - Clinical Medical Center Osijek, Osijek, HR, ⁶University Psychiatric Hospital Sveti Ivan, Zagreb, HR, ⁷KBC Split, Split, HR
- 15:20 - 15:25 **42P - Real-life data on treatment with poly (ADP-ribose) polymerase inhibitor**

(iPARP), in patients over 65 years of age with ovarian cancer: a current need.

M. Martinez Cutillas, Y. Garitaonandia Diaz, B. Nunez Garcia, M. Blanco Clemente, C. Traseira Puchol, R. Aguado, G. Visedo, A. González Sánchez, D. Ruiz De Domingo, M. Sánchez Del Corral, M.A. Gonzalez Del Alba Baamonde, J.C. Sanchez Gonzalez, B. Cantos Sanchez De Ibarquen, M. Mendez Garcia, M. Provencio Pulla, C. Maximiano Alonso, University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES

15:25 - 15:30

43P - Malignant bowel obstruction in advanced ovarian cancer: a retrospective analysis of patients supported with parenteral nutrition

R. Wight¹, A. Murphy², J. Bower¹, R. Morgan¹, L. Flanagan¹, S. Maycock¹, S. Lal³, A. Teubner³, A. Abraham³, C. Mitchell¹, J. Hasan¹, G. Jayson¹, A. Clamp¹, Z. Salih¹, ¹The Christie NHS Foundation Trust, Manchester, GB, ²Nepean Cancer Care Centre, Kingswood, AU, ³Salford Royal, Salford, GB

15:30 - 15:35

44TiP - ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab vs placebo + paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer

N. Colombo¹, R. Coleman², X. Wu³, F. Kose⁴, R. Wenham⁵, A. Sebastianelli⁶, K. Hasegawa⁷, E. Zsiros⁸, T. De La Motte Rouge⁹, M. Bidzinski¹⁰, I. Mcneish¹¹, J. Sehouli¹², J. Korach¹³, P. Debruyne¹⁴, J.-W. Kim¹⁵, A. De Melo¹⁶, X. Peng¹⁷, A. Bogusz¹⁷, K. Yamada¹⁷, B. Monk¹⁸, ¹IEO - Istituto Europeo di Oncologia, Milan, IT, ²Texas Oncology-The Woodlands, The Woodlands, US, ³Fudan University Shanghai Cancer Center, Shanghai, CN, ⁴Baskent University, Adana, TR, ⁵Moffitt Cancer Center, Tampa, US, ⁶CHU de Québec-Université Laval, Quebec, CA, ⁷Saitama Medical University International Medical Center, Hidaka, JP, ⁸Roswell Park Comprehensive Cancer Center, Buffalo, US, ⁹Centre Eugène-Marquis, Rennes, FR, ¹⁰Faculty of Medical Sciences and Health Sciences Kazimierz Pulaski University of Technology and Humanities, Radom, PL, ¹¹Imperial College London - Hammersmith Campus, London, GB, ¹²Charité Universitätsmedizin Berlin, Berlin, DE, ¹³Sheba Medical Center, Tel Aviv University, Tel Aviv, IL, ¹⁴Medical Technology Research Institute (MTRI), School of Life Sciences, Anglia Ruskin University, Cambridge, GB, ¹⁵Seoul National University Hospital, Seoul, KR, ¹⁶Instituto Nacional de Câncer, Brazilian National Cancer Institute, Rio de Janeiro, BR, ¹⁷Merck & Co., Inc., Kenilworth, US, ¹⁸University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, US

15:35 - 15:40

45TiP - A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bev vs Carboplatin-Paclitaxel-Bev-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, selected according to HRD status, in patients with advanced ovarian cancer

G. Scambia¹, V. Salutari¹, L. Musacchio², S. Siena³, S. Pignata⁴, L. Zavallone⁵, G. Valabrega⁶, G. Cormio⁷, A.M. Mosconi⁸, C. Ricci², V. Ghizzoni¹, M.V. Carbone¹, E. Giudice¹, F. Camarda¹, C. Nero², F. Tronconi⁹, D. Lorusso¹⁰, ¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ³ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, ⁴Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, IT, ⁵ASL Biella - Ospedale degli Infermi, Biella, IT, ⁶IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ⁷Policlinico di Bari - Ospedale Giovanni XXIII, Bari, IT, ⁸Ospedale Santa Maria della Misericordia - URP, Perugia, IT, ⁹Università Politecnica delle Marche, Ancona, IT, ¹⁰Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT

- 15:40 - 15:45 **47P - Quality of life after extended pelvic exenterations**
D. Cibula¹, S. Lednický¹, E. Höschlová², J. Slama¹, M. Wiesnerová³, P. Mitáš⁴, Z. Matejovský⁵, L. Dostálek¹, M. Borcinová¹, ¹General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, Prague, CZ, ²Faculty of Arts, Charles University in Prague, Czech Republic, Prague, CZ, ³Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, Brno, CZ, ⁴Second surgical clinic - cardiovascular surgery, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague, CZ, ⁵FN Bulovka - University Hospital Bulovka, Prague, CZ
- 15:45 - 15:50 **48P - Clinical profile and treatment outcomes of Malignant Mixed Mullerian tumor of the uterus**
N. Vijayaraghavan, K. Latha, S. Elumalai, G. Dinakaran Gangadaran, Madras Medical College, Chennai, IN
- 15:50 - 15:55 **49P - Impact of nutritional factors in response and survival of patients with Gestational Trophoblastic Neoplasia**
K. Roque¹, M.A. Galvez Nino¹, M. Castro¹, H.D. Vallejos², R. Ruiz¹, N.I. Valdiviezo Lama¹, O. Coanqui Gonzales³, M. Olivera¹, J. Perez¹, A. Lopez⁴, C. Velarde¹, R. De Mello⁵, L.A. Mas Lopez¹, ¹INEN - Instituto Nacional de Enfermedades Neoplasicas, Lima, PE, ²Peoples' Friendship University of Russia (RUDN University), Moscow, RU, ³Inen, Lima, PE, ⁴Department of Gynecological Surgery, National Institute of Neoplastic Diseases, Lima, Peru, Lima, PE, ⁵University of Algarve - Faculty of Sciences and Technology (FCT), Faro, PT
- 15:55 - 16:00 **50P - Direct-acting oral anticoagulants prescribing pattern in patients with gynaecological cancer: results of a survey among Italian oncologists belonging to MITO group and AIOM society**
V. Tuninetti¹, A. Milani², S. Pignata³, D. Lorusso⁴, D. Castaldo⁵, U. De Giorgi⁶, A. Savarese⁷, N. Biglia⁸, G. Scandurra⁹, S. Testa¹⁰, G. Mangili¹¹, M. Di Maio¹², M. Turinetti¹², S. Mammoliti¹³, G. Scotto¹², G. Artioli¹⁴, G. Valabrega¹⁵, ¹University of Turin, Turin, IT, ²ASL TO5, Turin, Italy, Carmagnola, IT, ³Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, IT, ⁴Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT, ⁵Segreteria Multicenter Italian Trials in Ovarian Cancer and gynecologic malignancies (MITO) Group, Napoli, IT, ⁶IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, IT, ⁷IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, ⁸Azienda Ospedaliera Ordine Mauriziano - Presidio Umberto I, Torino, IT, ⁹Humanitas Centro Catanese di Oncologia, Catania, IT, ¹⁰Struttura Complessa di Anestesia e Rianimazione, Carmagnola, IT, ¹¹IRCCS Ospedale San Raffaele, Milan, IT, ¹²Division of Medical Oncology, Ordine Mauriziano Hospital, Torino, IT, ¹³IRCCS Ospedale Policlinico San Martino, Genova, IT, ¹⁴Presidio Ospedaliero Mirano, Mirano, IT, ¹⁵IRCCS - Istituto di Candiolo - FPO, Candiolo, IT

13:00 - 14:00	GSK - Using biomarkers to guide targeted therapy in gynaecological cancers	Auditorium 1A
	Moderation: A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES	
13:00 - 13:05	Welcome and introduction	
	<u>A. Oaknin</u> , Vall d'Hebron University Hospital, Barcelona, ES	
13:05 - 13:22	Can biomarkers guide targeted treatment for recurrent endometrial cancer?	
	<u>G. Valabrega</u> ¹ , A. Oaknin ² , X. Matias-Guiu ³ , C. Grimm ⁴ , ¹ IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ² Vall d'Hebron University Hospital, Barcelona, ES, ³ University of Lleida, Hospitalet de Llobregat, ES, ⁴ Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT	
13:22 - 13:27	Q&A from audience	
	<u>T. Panelists</u> , Valencia, ES	
13:27 - 13:44	How and when should HRD testing guide treatment for 1L advanced ovarian cancer?	
	<u>C. Grimm</u> ¹ , A. Oaknin ² , X. Matias-Guiu ³ , G. Valabrega ⁴ , ¹ Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT, ² Vall d'Hebron University Hospital, Barcelona, ES, ³ University of Lleida, Hospitalet de Llobregat, ES, ⁴ IRCCS - Istituto di Candiolo - FPO, Candiolo, IT	
13:44 - 13:49	Q&A from audience	
	<u>T. Panelists</u> , Valencia, ES	
13:49 - 14:00	Final discussion and closing remarks	
	<u>A. Oaknin</u> , Vall d'Hebron University Hospital, Barcelona, ES	
14:15 - 14:45	Keynote lecture: Changes in practice and research breakthroughs in the treatment of gynaecological cancers	Auditorium 1A
	Moderation: D. Lorusso, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT	
14:15 - 14:20	Introduction	
	<u>D. Lorusso</u> , Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT	
14:20 - 14:40	Changes in practice and research breakthroughs in the treatment of gynaecological cancers	
	<u>E. Pujade-Lauraine</u> , ARCAGY-GINECO, Paris, FR	

14:50 - 15:50	Shall all patients regardless of biomarker status receive immunotherapy in cervical cancer?	Auditorium 1A
	Moderation: M.R. Mirza ¹ , D. Lorusso ² , ¹ Rigshospitalet, Copenhagen, DK, ² Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT	
14:50 - 15:00	Introduction and first vote <u>M.R. Mirza</u> , Rigshospitalet, Copenhagen, DK	
15:00 - 15:20	Pro <u>N. Colombo</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
15:20 - 15:40	Con <u>A. Oaknin</u> , Vall d'Hebron University Hospital, Barcelona, ES	
15:40 - 15:50	Second vote and conclusions <u>D. Lorusso</u> , Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT	
16:15 - 17:45	Ovarian cancer management in the PARP inhibitor era	Auditorium 1A
	Moderation: S. Banerjee ¹ , I. Romero ² , ¹ The Royal Marsden Hospital - Chelsea, London, GB, ² Valencia, ES	
16:15 - 16:40	The role of surgery in newly-diagnosed and recurrent ovarian cancer in the era of targeted therapies <u>S. Mahner</u> , LMU - Ludwig Maximilians University - Grosshadern, Munich, DE	
16:40 - 17:05	How to make the best of PARP inhibitor therapy: When, who and how? <u>R. Coleman</u> , Texas Oncology-The Woodlands, The Woodlands, US	
17:05 - 17:30	How to treat ovarian cancer post and beyond PARP inhibitors? <u>S. Lheureux</u> , University Health Network - Princess Margaret Cancer Center, Toronto, CA	
17:30 - 17:45	Live Q&A	

18:00 - 19:00	Eisai - Recent advances in the management of endometrial cancer and their impact on the clinical practice Moderation: A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES	Auditorium 1A
18:00 - 18:05	Opening &#38; Introduction <u>A. Oaknin</u> , Vall d'Hebron University Hospital, Barcelona, ES	
18:05 - 18:25	Recent advances in the management of endometrial cancer <u>A. Oaknin</u> , Vall d'Hebron University Hospital, Barcelona, ES	
18:25 - 18:40	Patient case study &#38; discussion: The choice of therapy in dMMR disease <u>C. Marth</u> , Innsbruck Medical University, Innsbruck, AT	
18:40 - 18:55	Patient case study &#38; discussion: The challenges of managing adverse events <u>P. Harter</u> , Essen, DE	
18:55 - 19:00	Summary and session close <u>A. Oaknin</u> , Vall d'Hebron University Hospital, Barcelona, ES	

18.06.2022

- 08:30 - 10:00 The evolving landscape in cervical cancer treatment Auditorium 1A**
Moderation: D. Lorusso¹, A. Oaknin², ¹Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT, ²Vall d'Hebron University Hospital, Barcelona, ES
- 08:30 - 08:55 **Surgical approach in early-stage cervical cancer: Keeping the principles and reducing morbidity**
D. Cibula, General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, Prague, CZ
- 08:55 - 09:20 **Is immunotherapy ready for prime time in cervical cancer?**
D. Lorusso, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT
- 09:20 - 09:45 **The role of ADC and other targeted therapies in the treatment of recurrent/metastatic cervical cancer**
N. Concin, Landeskrankenhaus - Universitaetskliniken Innsbruck, Innsbruck, AT
- 09:45 - 10:00 **Live Q&A**

10:30 - 12:00	Clinical trial highlights	Auditorium 1A
	Moderation: S. Banerjee ¹ , N. Concin ² , ¹ The Royal Marsden Hospital - Chelsea, London, GB, ² Landeskrankenhaus - Universitaetskliniken Innsbruck, Innsbruck, AT	
10:30 - 10:40	Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase III trial <u>N. Li</u> , Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN	
10:40 - 10:50	ATHENA (GOG-3020/ENGOT-ov45): A randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer <u>R. Kristeleit</u> , Guys and St Thomas NHS Trust, London, GB	
10:50 - 11:05	Invited Discussant of PRIME and ATHENA-MONO studies <u>M.R. Mirza</u> , Rigshospitalet, Copenhagen, DK	
11:05 - 11:15	Live Q&A	
11:15 - 11:25	SIENDO/ENGOT-EN5: A randomized phase III trial of maintenance with selinexor/placebo after combination chemotherapy in patients with advanced or recurrent endometrial cancer <u>V. Makker</u> , Memorial Sloan-Kettering Cancer Center, New York City, US	
11:25 - 11:35	MITO 23: A randomized phase III trial on trabectedin vs physician choice chemotherapy in BRCA mut and BRCAness ovarian cancer <u>D. Lorusso</u> , Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT	
11:35 - 11:50	Invited Discussant of SIENDO/ENGOT-EN5 and MITO 23 studies <u>I. Ray-Coquard</u> , Centre Léon Bérard, University Claude Bernard, Lyon, FR	
11:50 - 12:00	Live Q&A	
12:05 - 12:50	YO Vesalius talk: How to succeed as a young investigator	Foyer
	Moderation: S. Banerjee ¹ , N. Concin ² , E. Mariamidze ³ , M. Kfoury ⁴ , ¹ The Royal Marsden Hospital - Chelsea, London, GB, ² Landeskrankenhaus - Universitaetskliniken Innsbruck, Innsbruck, AT, ³ Tbilisi, GE, ⁴ Villejuif, FR	
13:00 - 14:00	Mini Oral session	Auditorium 1A
	Moderation: J.E. Kurtz ¹ , I. Mcneish ² , L. Loverix ³ , ¹ Strasbourg, FR, ² Imperial College London - Hammersmith Campus, London, GB, ³ University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	

- 13:00 - 13:05 **20MO - Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician's choice (TPC)**
- D. Lorusso¹, N. Colombo², A. Casado Herráez³, A.D. Santin⁴, E. Colomba⁵, D. Miller⁶, K. Fujiwara⁷, S. Pignata⁸, S. Baron-Hay⁹, I. Ray-Coquard¹⁰, R. Shapira-Frommer¹¹, Y.M. Kim¹², M. McCormack¹³, R. Massaad¹⁴, A. Martin Nguyen¹⁵, Q. Zhao¹⁶, J. Mckenzie¹⁶, V.S. Prabhu¹⁵, V. Makker¹⁷, ¹Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT, ²IEO - Istituto Europeo di Oncologia, Milan, IT, ³San Carlos University Teaching Hospital, Madrid, ES, ⁴Yale University School of Medicine, New Haven, US, ⁵Gustave Roussy Cancerology Institute, Villejuif, GINECO Group, FR, ⁶University of Texas Southwestern Medical Center, Dallas, US, ⁷Saitama Medical University International Medical Center, Hidaka, JP, ⁸Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, IT, ⁹Royal North Shore Hospital, St Leonards, AU, ¹⁰Centre Léon Bérard, University Claude Bernard, Lyon, FR, ¹¹Sheba Medical Center, Ramat, IL, ¹²Asan Medical Center, University of Ulsan, Seoul, KR, ¹³University College London Hospitals NHS Foundation Trust, London, GB, ¹⁴MSD (Europe), Brussels, BE, ¹⁵Merck & Co. Inc., Kenilworth, US, ¹⁶Eisai Inc., Nutley, US, ¹⁷Memorial Sloan-Kettering Cancer Center, New York City, US
- 13:05 - 13:15 **Invited Discussant of abstract 20MO**
- J.E. Kurtz, Strasbourg, FR
- 13:15 - 13:20 **21MO - Limited benefit of molecular profiling in patients with low-grade endometrial cancer**
- S. Vrede¹, J. Kasius², J. Bulten³, W.J. Van Weelden⁴, D. Boll⁵, M.C. Vos⁶, A. Van Altena³, X. Matias-Guiu⁷, J. Asberger⁸, E. Colas⁹, A. Gil-Moreno⁹, J. Huvila¹⁰, V. Weinberger¹¹, F. Amant¹², M. Snijders¹³, H. Küsters-Vandeveld¹³, A. Eijkelenboom¹, R. Kruitwagen¹⁴, C. Reijnen³, J. Pijnenborg⁴, ¹Radboud University Medical Centre Nijmegen, Nijmegen, NL, ²Amsterdam University Medical Center (UMC) - locatie Academic Medical Center (AMC), Amsterdam, NL, ³Radboud University Medical Center, Nijmegen, Nijmegen, NL, ⁴Radboud University Medical Center, Nijmegen, NL, ⁵Institution Catharina Ziekenhuis, Eindhoven, NL, ⁶ETZ - Elisabeth-TweeSteden Hospital, Tilburg, NL, ⁷University of Lleida, Hospitalet de Llobregat, ES, ⁸University Medical Center Freiburg, Freiburg im Breisgau, DE, ⁹Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰University of Turku, Turku, FI, ¹¹Masaryk University Hospital Brno FN Brno Bohunice, Brno, CZ, ¹²UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹³Canisius Wilhelmina Ziekenhuis CWZ Hospital, Nijmegen, NL, ¹⁴Maastricht University Medical Center (MUMC), Maastricht, NL
- 13:20 - 13:25 **27MO - Integrated digital pathology and single-cell analysis identify the spatial and temporal evolution of immune cells networks in epithelial ovarian cancer**
- E. Ghisoni¹, F. Benedetti², P. Cunnea³, N. Fahr², D. Gulhan⁴, A. Minasyan², M. Desbuisson², A. Grimm², D. Barras², J. Dagher⁵, E. Fortis⁶, S. Rusakiewicz⁶, S. Tissot⁶, S.A. Mastroyannis⁷, E. Swisher⁸, L. Kandalaf⁶, J. Tanyi⁷, C. Fotopoulou³, G. Coukos⁹, D. Dangaj², ¹UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Epalinges, CH, ²UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Lausanne, CH, ³Imperial College of London, London, GB, ⁴Harvard Medical School, Boston, US, ⁵CHUV - Lausanne University Hospital, Lausanne, CH, ⁶Center of Experimental Therapeutics,

Lausanne, CH, ⁷University Of Pennsylvania, Philadelphia, US, ⁸University of Washington, Seattle, US, ⁹CHUV-UNIL and Ludwig Institute for Cancer Research - Lausanne Branch, Lausanne, CH

- 13:25 - 13:35 **Invited Discussant of abstracts 21MO and 27MO**
I. Mcneish, Imperial College London - Hammersmith Campus, London, GB
- 13:35 - 13:40 **28MO - Real-world whole sequencing data of ovarian cancer patients**
I. Funingana¹, J. Ambrose², K. Hosking³, N. Demiris³, A. Sosinsky⁴, J. Brenton⁵,
¹University of Cambridge School of Clinical Medicine, Cambridge, GB, ²Genomics England, London, GB, ³Addenbrooke's Hospital, Cambridge, GB, ⁴QMUL, London, GB, ⁵CRUK - Cancer Research UK Cambridge Institute - University of Cambridge, Cambridge, GB
- 13:40 - 13:50 **Invited Discussant of abstract 28MO**
L. Loverix, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
- 13:50 - 14:00 **Q&A and discussion**
- 14:15 - 15:45 Managing the consequences of cancer treatments Auditorium 1A**
Moderation: S. Banerjee¹, C. Falandry², ¹The Royal Marsden Hospital - Chelsea, London, GB, ²Lyon Sud Hospital Center, Pierre Benite, FR
- 14:15 - 14:35 **Fertility-preservation option in gynaecological cancer**
F. Amant, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
- 14:35 - 14:55 **How to optimise older patients for cancer treatments?**
C. Falandry, Lyon Sud Hospital Center, Pierre Benite, FR
- 14:55 - 15:15 **Management of immunotherapy and targeted therapies-induced toxicities**
A.J. Gonzalez Martin, Clinica Universidad de Navarra, Madrid, ES
- 15:15 - 15:35 **Radiotherapy-related toxicities in gynaecological cancers**
A. Taylor, Royal Marsden Hospital NHS Foundation Trust, London, GB
- 15:35 - 15:45 **Live Q&A**

16:10 - 17:40	Rare gynaecological cancers	Auditorium 1A
	Moderation: I. Ray-Coquard ¹ , D.S. Tan ² , ¹ Centre Léon Bérard, University Claude Bernard, Lyon, FR, ² NUHS - National University Health System, Singapore, SG	
16:10 - 16:35	Histo-molecular classification of rare tumours, predictive markers and druggable targets	
	<u>I. Mcneish</u> , Imperial College London - Hammersmith Campus, London, GB	
16:35 - 17:00	Current management and ongoing clinical trials	
	<u>D.S. Tan</u> , NUHS - National University Health System, Singapore, SG	
17:00 - 17:25	Future clinical research and unmet needs	
	<u>I. Ray-Coquard</u> , Centre Léon Bérard, University Claude Bernard, Lyon, FR	
17:25 - 17:40	Discussion	
17:40 - 17:45	Closing remarks	Auditorium 1A
	Moderation: S. Banerjee ¹ , D. Lorusso ² , ¹ The Royal Marsden Hospital - Chelsea, London, GB, ² Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT	